Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses

IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation

(2021) Adaobi Amobi-McCloud et al.   Frontiers in Immunology

Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape

(2020) Constance J. Martin et al.   Science Translational Medicine

Creation and analysis of biochemical constraint-based models using the COBRA Toolbox v.3.0

(2019) Laurent Heirendt et al.   Nature Protocols

Effects of Epacadostat on Brain Extracellular Fluid Concentrations of Serotonin -- An Intracerebral Microdialysis Study in Sprague-Dawley Rats

(2019) Yan Zhang et al.   DRUG METABOLISM AND DISPOSITION

Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts

(2019) Mark A. Eckert et al.   NATURE

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

(2019) Georgina V Long et al.   LANCET ONCOLOGY

The therapeutic potential of targeting tryptophan catabolism in cancer

(2019) Christiane A. Opitz et al.   BRITISH JOURNAL OF CANCER

The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer

(2018) Harvey R. Fernandez et al.   CELL DEATH AND DIFFERENTIATION

Serotonin decreases the production of Th1/Th17 cytokines and elevates the frequency of regulatory CD4+ T-cell subsets in multiple sclerosis patients

(2018) Priscila M. Sacramento et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Ruthenium counterstaining for imaging mass cytometry

(2018) Raúl Catena et al.   JOURNAL OF PATHOLOGY

Recon3D enables a three-dimensional view of gene variation in human metabolism

(2018) Elizabeth Brunk et al.   NATURE BIOTECHNOLOGY

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

(2018) Thomas Duhen et al.   Nature Communications

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

(2018) Tara C. Mitchell et al.   JOURNAL OF CLINICAL ONCOLOGY

Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study.

(2018) Adil Daud et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond

(2018) Alexander J. Muller et al.   Seminars in Immunopathology

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer

(2017) Rebecca Kristeleit et al.   GYNECOLOGIC ONCOLOGY

Nicotinamide N -Methyltransferase: More Than a Vitamin B3 Clearance Enzyme

(2017) Pavlos Pissios   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Complex heatmaps reveal patterns and correlations in multidimensional genomic data

(2016) Zuguang Gu et al.   BIOINFORMATICS

Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies

(2016) Jack G. Shi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Phosphoribosyl Diphosphate (PRPP): Biosynthesis, Enzymology, Utilization, and Metabolic Significance

(2016) Bjarne Hove-Jensen et al.   MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

E-Flux2 and SPOT: Validated Methods for Inferring Intracellular Metabolic Flux Distributions from Transcriptomic Data

(2016) Min Kyung Kim et al.   PLoS One

NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus

(2015) Carles Cantó et al.   Cell Metabolism

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

limma powers differential expression analyses for RNA-sequencing and microarray studies

(2015) Matthew E. Ritchie et al.   NUCLEIC ACIDS RESEARCH

1-Methyl-D-Tryptophan Potentiates TGF-β-Induced Epithelial-Mesenchymal Transition in T24 Human Bladder Cancer Cells

(2015) Rodrigo Barbosa Oliveira Brito et al.   PLoS One

Glutamine Oxidation Maintains the TCA Cycle and Cell Survival during Impaired Mitochondrial Pyruvate Transport

(2014) Chendong Yang et al.   MOLECULAR CELL

Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry

(2014) Charlotte Giesen et al.   NATURE METHODS

NAD+ protects against EAE by regulating CD4+ T-cell differentiation

(2014) Stefan G. Tullius et al.   Nature Communications

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink

(2013) Olesya A Ulanovskaya et al.   Nature Chemical Biology

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

graphite - a Bioconductor package to convert pathway topology to gene network

(2012) Gabriele Sales et al.   BMC BIOINFORMATICS

Indoleamine 2,3-dioxygenase: From catalyst to signaling function

(2012) Francesca Fallarino et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development

(2012) Courtney Smith et al.   Cancer Discovery

Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives

(2011) J. Godin-Ethier et al.   CLINICAL CANCER RESEARCH

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

(2010) X. Liu et al.   BLOOD

Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors

(2010) H. K. Koblish et al.   MOLECULAR CANCER THERAPEUTICS

flowCore: a Bioconductor package for high throughput flow cytometry

(2009) Florian Hahne et al.   BMC BIOINFORMATICS

Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data

(2009) Anne von Heideman et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer

(2009) Feng Qian et al.   CANCER RESEARCH

Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma

(2009) Tomoko Inaba et al.   GYNECOLOGIC ONCOLOGY

Interpreting Expression Data with Metabolic Flux Models: Predicting Mycobacterium tuberculosis Mycolic Acid Production

(2009) Caroline Colijn et al.   PLoS Computational Biology